This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignees: Cellid Co., Ltd., Seoul National University. Active years: 2011-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011-2016
Title: Hyun-Jeong Ko: Innovator in Immuno-Therapeutic Vaccines
Introduction
Hyun-Jeong Ko is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of immunotherapy, particularly in the development of vaccines aimed at treating infectious diseases and cancer. With a total of 2 patents, his work is paving the way for innovative therapeutic solutions.
Latest Patents
Hyun-Jeong Ko's latest patents include a vaccine comprising monocyte or immature myeloid cells (IMC) loaded with the ligand of natural killer T cells and an antigen. This immuno-therapeutic and prophylactic vaccine is designed for the prevention and treatment of infectious diseases or cancer. The invention utilizes monocytes or IMCs, which are more easily obtainable than dendritic cells, to induce significant cytotoxic T lymphocyte responses and provide therapeutic effects on malignant tumors.
Another notable patent is a B cell-based vaccine loaded with the ligand of natural killer T cells and an antigen. This vaccine is also aimed at preventing and treating diseases, particularly as an antitumor immunotherapeutic agent. The B cells used in this vaccine are similarly accessible compared to dendritic cells and can induce comparable cytotoxic T lymphocyte responses, offering both prophylactic and therapeutic effects on solid and metastatic tumors.
Career Highlights
Hyun-Jeong Ko has worked with notable organizations such as Cellid Co., Ltd. and Seoul National University. His experience in these institutions has contributed to his expertise in vaccine development and immunotherapy.
Collaborations
Some of his coworkers include Chang-Yuil Kang and Yeon-Jeong Kim, who have collaborated with him on various projects related to immunotherapy and vaccine research.
Conclusion
Hyun-Jeong Ko's innovative work in the field of immuno-therapeutic vaccines demonstrates his commitment to advancing medical science. His patents reflect a promising future for the treatment of infectious diseases and cancer through novel vaccine strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile